Castrate-Resistant Prostate Cancer Market Report and Forecast 2025-2034
Description
The castrate-resistant prostate cancer market size was valued at USD 11.19 Billion in 2024, driven by the incidence of prostate cancer, along with development of new therapies globally. The market is expected to grow at a CAGR of 8.60% during the forecast period of 2025-2034, with the values likely to reach USD 25.53 Billion by 2034.
Castrate-Resistant Prostate Cancer: Introduction
Castrate-Resistant Prostate Cancer (CRPC) is an advanced type of prostate cancer wherein the body stops responding to treatments. Prostate cancer is commonly treated by blocking the male sex hormone, testosterone, that promotes cancer cells growth. However, in the case of advanced castrate-resistant prostate cancer, the body stops reacting to hormone therapy.
CRPC can be metastatic or nonmetastatic. In metastatic CRPC (mCRPC), cancer spreads to other parts of the body. Common symptoms include pain while urinating, blood in urine, weight loss, fatigue, or shortness of breath. The treatment involves slowing the cancer growth and controlling the symptoms with the help of chemotherapy, immunotherapy, gene therapy and others.
In non-metastatic CRPC (nmCRPC), the cancer is only present in the prostate region.
Castrate-Resistant Prostate Cancer Market Analysis
Prostate cancer is the second most prominent cancer type in males affecting approximately 15.1% of the population. The treatment consists of radiation, chemotherapy, hormone therapy, targeted therapy, immunotherapy, and gene therapy. Hormone therapy is mostly preferred and constitutes treatments like androgen deprivation therapy (ADT), bilateral orchiectomy, LHRH agonists, androgen receptor (AR) inhibiting drugs such as Apalutamide, Darolutamide and Enzalutamide, and GnRH antagonists. Although these treatments have brought major improvements, there are several side effects one may experience with it. Hence, there has been extensive research in the domain fuelling castrate-resistant prostate cancer market value.
Radioligand therapy has gained attention of the scientists in the recent years. It sends radioactive emitters directly to the tumour associated targets. These radioactive atoms only target the DNA of cancer cells and provides an edge over the conventional external-beam radiation therapy, which cannot target the tumour cells directly. Currently, a combination of 177Lu-PSMA-617 with actinium-225 in conjunction to the J591 monoclonal antibody, is under first and second phase trials.
Molecular targeted therapy is another latest and advancing fields of CRPC treatment. In August 2024, FDA approved the combination of Enzalutamide (Xtandi) with Talazoparib (Talzenna) to treat metastatic Castrate-Resistant Prostate Cancer. Enzalutamide works by blocking hormones that accelerate cancer cell growth followed by Talazoparib, which blocks the activities of PARP (DNA repairing) protein. This makes cancer cell survival difficult. Talazoparib is the third PARP blocking drug to receive FDA approval. As a result, the castrate-resistant prostate cancer market growth is certain with the increasing research and development in oncology.
Castrate-Resistant Prostate Cancer Market Segmentation
“Castrate-Resistant Prostate Cancer Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Type
The North American territory dominates the castrate-resistant prostate cancer market share as it is the second leading cause of cancer death in the region. With the prevalence of a geriatric population and unhealthy lifestyle changes, the number of morbidities has grown in the area. Therefore, the government and key players of healthcare industry have taken strict measures to spread awareness about the disease in the relevant population. The presence of a proper infrastructure also enables the scientists to continue research for effective treatment.
The European territory along with Asia-pacific region can also observe a significant surge in the market, especially due to the efforts of the government and educational institutes to boost effective research and development. The Asian region being home world’s largest geriatric population can be a large market in the forecast period.
Castrate-Resistant Prostate Cancer Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Castrate-Resistant Prostate Cancer: Introduction
Castrate-Resistant Prostate Cancer (CRPC) is an advanced type of prostate cancer wherein the body stops responding to treatments. Prostate cancer is commonly treated by blocking the male sex hormone, testosterone, that promotes cancer cells growth. However, in the case of advanced castrate-resistant prostate cancer, the body stops reacting to hormone therapy.
CRPC can be metastatic or nonmetastatic. In metastatic CRPC (mCRPC), cancer spreads to other parts of the body. Common symptoms include pain while urinating, blood in urine, weight loss, fatigue, or shortness of breath. The treatment involves slowing the cancer growth and controlling the symptoms with the help of chemotherapy, immunotherapy, gene therapy and others.
In non-metastatic CRPC (nmCRPC), the cancer is only present in the prostate region.
Castrate-Resistant Prostate Cancer Market Analysis
Prostate cancer is the second most prominent cancer type in males affecting approximately 15.1% of the population. The treatment consists of radiation, chemotherapy, hormone therapy, targeted therapy, immunotherapy, and gene therapy. Hormone therapy is mostly preferred and constitutes treatments like androgen deprivation therapy (ADT), bilateral orchiectomy, LHRH agonists, androgen receptor (AR) inhibiting drugs such as Apalutamide, Darolutamide and Enzalutamide, and GnRH antagonists. Although these treatments have brought major improvements, there are several side effects one may experience with it. Hence, there has been extensive research in the domain fuelling castrate-resistant prostate cancer market value.
Radioligand therapy has gained attention of the scientists in the recent years. It sends radioactive emitters directly to the tumour associated targets. These radioactive atoms only target the DNA of cancer cells and provides an edge over the conventional external-beam radiation therapy, which cannot target the tumour cells directly. Currently, a combination of 177Lu-PSMA-617 with actinium-225 in conjunction to the J591 monoclonal antibody, is under first and second phase trials.
Molecular targeted therapy is another latest and advancing fields of CRPC treatment. In August 2024, FDA approved the combination of Enzalutamide (Xtandi) with Talazoparib (Talzenna) to treat metastatic Castrate-Resistant Prostate Cancer. Enzalutamide works by blocking hormones that accelerate cancer cell growth followed by Talazoparib, which blocks the activities of PARP (DNA repairing) protein. This makes cancer cell survival difficult. Talazoparib is the third PARP blocking drug to receive FDA approval. As a result, the castrate-resistant prostate cancer market growth is certain with the increasing research and development in oncology.
Castrate-Resistant Prostate Cancer Market Segmentation
“Castrate-Resistant Prostate Cancer Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Type
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Others
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Others
- Oral
- Parenteral
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- United States
- EU-4 and the United Kingdom
- Japan
The North American territory dominates the castrate-resistant prostate cancer market share as it is the second leading cause of cancer death in the region. With the prevalence of a geriatric population and unhealthy lifestyle changes, the number of morbidities has grown in the area. Therefore, the government and key players of healthcare industry have taken strict measures to spread awareness about the disease in the relevant population. The presence of a proper infrastructure also enables the scientists to continue research for effective treatment.
The European territory along with Asia-pacific region can also observe a significant surge in the market, especially due to the efforts of the government and educational institutes to boost effective research and development. The Asian region being home world’s largest geriatric population can be a large market in the forecast period.
Castrate-Resistant Prostate Cancer Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanofi
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Astellas Pharma, Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Novartis AG
- Eli Lilly and Company
- Merck & Co., Inc.
- Allergan
- AstraZeneca
- Cipla Inc.
- Amneal Pharmaceuticals LLC
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Castrate-Resistant Prostate Cancer Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Castrate-Resistant Prostate Cancer Epidemiology Analysis-7MM
- 5.1 Epidemiology Overview (2018-2034)
- 5.2 United States Castrate-Resistant Prostate Cancer Epidemiology (2018-2034)
- 5.3 EU-4 and United Kingdom Castrate-Resistant Prostate Cancer Epidemiology (2018-2034)
- 5.4 Japan Castrate-Resistant Prostate Cancer Epidemiology (2018-2034)
- 6 Castrate-Resistant Prostate Cancer Market Overview
- 6.1 Castrate-Resistant Prostate Cancer Market Historical Value (2018-2024)
- 6.2 Castrate-Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 7 Castrate-Resistant Prostate Cancer Market Landscape
- 7.1 Castrate-Resistant Prostate Cancer: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Castrate-Resistant Prostate Cancer: Product Landscape
- 7.2.1 Analysis by Therapy Type
- 7.2.2 Analysis by Drug Class
- 7.2.3 Analysis by Route of Administration
- 8 Castrate-Resistant Prostate Cancer Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Castrate-Resistant Prostate Cancer Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Castrate-Resistant Prostate Cancer Market Segmentation
- 11.1 Castrate-Resistant Prostate Cancer Market by Therapy Type
- 11.1.1 Market Overview
- 11.1.2 Hormonal Therapy
- 11.1.3 Immunotherapy
- 11.1.4 Chemotherapy
- 11.1.5 Others
- 11.2 Castrate-Resistant Prostate Cancer Market by Therapy Drug Class
- 11.2.1 Market Overview
- 11.2.2 Antineoplastic
- 11.2.3 Non-steroidal Antiandrogen
- 11.2.4 Corticosteroids
- 11.2.5 Others
- 11.3 Castrate-Resistant Prostate Cancer Market by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Oral
- 11.3.3 Parenteral
- 11.4 Castrate-Resistant Prostate Cancer Market by Distribution Channel
- 11.4.1 Market Overview
- 11.4.2 Hospital Pharmacy
- 11.4.3 Retail Pharmacy
- 11.4.4 Online Pharmacy
- 11.5 Castrate-Resistant Prostate Cancer Market by Region -7MM
- 11.5.1 Market Overview
- 11.5.2 United States
- 11.5.3 EU-4 and the United Kingdom
- 11.5.4 Japan
- 12 United States Castrate-Resistant Prostate Cancer Market
- 12.1 U.S. Castrate-Resistant Prostate Cancer Market Historical Size (2018-2024)
- 12.2 U.S. Castrate-Resistant Prostate Cancer Market Forecast Size (2025-2034)
- 12.3 Market Size by Therapeutic Class
- 13 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market
- 13.1 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Historical Size (2018-2024)
- 13.2 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Forecast Size (2025-2034)
- 13.3 Market Size by Therapeutic Class
- 14 Japan Castrate-Resistant Prostate Cancer Market
- 14.1 Japan Castrate-Resistant Prostate Cancer Market Historical Size (2018-2024)
- 14.2 Japan Castrate-Resistant Prostate Cancer Market Forecast Size (2025-2034)
- 14.3 Market Size by Therapeutic Class
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnership and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Sanofi
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Johnson & Johnson Services Inc.
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Pfizer Inc.
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Astellas Pharma, Inc.
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Bayer AG
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 F. Hoffmann-La Roche Ltd.
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Mylan N.V.
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Teva Pharmaceutical Industries Ltd.
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 GlaxoSmithKline plc
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Novartis AG
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Eli Lilly and Company
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 Merck & Co., Inc.
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Allergan
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 AstraZeneca
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 Cipla Inc.
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 21.16 Amneal Pharmaceuticals LLC
- 21.16.1 Financial Analysis
- 21.16.2 Product Portfolio
- 21.16.3 Demographic Reach and Achievements
- 21.16.4 Mergers and Acquisitions
- 21.16.5 Certifications
- 22 Castrate-Resistant Prostate Cancer - Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
